BioSpace News Archive

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three months ended March 31, 2021.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:

New findings from an American College of Cardiology’s (ACC) survey revealed more than half of cardiologists (57%) believe patient preparation may lead to better quality discussions around treatment options for heart valve disease (HVD)

Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that its CEO, Dr. Daniel Teper, will be presenting in the following industry conferences:

TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the first quarter ended March 31, 2021 and provided a business update.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Alison L. Hannah, M.D. to its Board of Directors.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal second quarter ended March 31, 2021.

Aveanna Healthcare Holdings Inc. (“Aveanna”) today announced that the company will release its first quarter results after the market close on Tuesday, May 25, 2021, to be followed by a conference call on Wednesday, May 26, 2021 at 10:00 a.m. (Eastern Time).

Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Chief Executive Officer, Keith Dionne, Ph.D., will present a company overview at the upcoming Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 8:15 a.m. ET.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today reported financial results for the quarter ended March 31, 2021 and provided corporate highlights.